Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Focal Seizure Clear all
Completed Phase 3 Interventional

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT00113165
View directory record Official record
Conditions
Epilepsy, Epilepsy, Partial
Interventions
LAMICTAL extended-release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383
View directory record Official record
Conditions
Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

NCT00596466
View directory record Official record
Conditions
Epilepsy
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT07594119
View directory record Official record
Conditions
Focal Seizure, Epilepsy, Focal Epilepsy
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Huntsville, Alabama • Bentonville, Arkansas • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 3 Interventional

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

NCT02134366
View directory record Official record
Conditions
Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions
Clobazam, Clonazepam, Lorazepam
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

NCT00522275
View directory record Official record
Conditions
Partial Epilepsies
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 4 Interventional

Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

NCT00215215
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Vagus Nerve Stimulation Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2006 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 10, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 1:44 PM EDT
Withdrawn Phase 3 Interventional

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
Rufinamide
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
12 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation

NCT02339376
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
Low-frequency repetitive transcranial magnetic stimulation, High-frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

NCT00552305
View directory record Official record
Conditions
Partial Epilepsies
Interventions
lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
Not listed
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

NCT00465517
View directory record Official record
Conditions
Partial Epilepsy, Catamenial Epilepsy
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 10, 2026, 1:44 PM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306
View directory record Official record
Conditions
Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 66 Years
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 10, 2026, 1:44 PM EDT
Completed No phase listed Observational Results available

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

NCT02392078
View directory record Official record
Conditions
Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
Not listed
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

NCT07233239
View directory record Official record
Conditions
Focal Seizures
Interventions
CBD-OS
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880
View directory record Official record
Conditions
Epilepsy
Interventions
Mangafodipir, Gadolinium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 10, 2026, 1:44 PM EDT